Biora Therapeutics, Inc. BIORQ
0.00
(0.22)
(100.00%)
as of 24 Sep
- Market cap
- $2.5M
- P/E
- 0.0×
Follow BIORQ
Growth Flags
show if company had growth for consecutive years
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
205.12 | 26.05 | 38.45 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(21.00) | (2.05) | (1.72) | — | |
P/B ratio |
0.00 | 0.00 | 0.00 | — | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | |
EV/Sales |
272.55 | 72.75 | 99.94 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(5.31) | (1.30) | (1.14) | — | |
EV/FCF |
(5.28) | (1.30) | (1.14) | — | |
Quick Ratio |
0.03 | 0.13 | 0.23 | 0.25 | |
Current Ratio |
0.05 | 0.20 | 0.28 | 0.30 | |
Net Debt/EBITDA |
(1.09) | (2.63) | (2.56) | (2.39) | |
Debt/Assets |
135.96% | 250.11% | 196.84% | 146.44% | |
Debt/Equity |
(0.18) | (0.51) | (0.45) | (0.45) | |
Asset Turnover |
0.04 | 0.03 | 0.01 | 0.00 | |
Operating CF/Net income |
0.47 | (1.69) | 2.98 | 0.89 | |
Capex/Depreciation |
(0.02) | (0.40) | 0.00 | (0.11) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
17,531.25% | 2,422.64% | 1,292.44% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
33,278.13% | 2,641.51% | 1,670.30% | 0.00% | |
Intangible Assets out of Total Assets |
0.42 | 0.33 | 0.26 | 0.19 | |
Share Based Compensation of Revenue |
4,003.13% | 494.65% | 283.95% | 0.00% | |
Graham Net Nets |
(0.63) | (4.37) | (5.07) | — | |
Graham Number |
26.68 | 77.55 | 144.64 | — | |
Earnings Yield |
(215.94%) | (169.67%) | (369.92%) | — | |
Free Cash Flow Yield |
(25.19%) | (215.38%) | (227.45%) | — | |
Revenue per Share |
0.00 | 0.09 | 0.19 | 0.00 | |
Operating CF per Share |
(0.24) | (3.07) | (4.27) | (8.71) | |
Capex per Share |
0.00 | (0.05) | 0.00 | (0.04) | |
Free Cash Flow per Share |
(0.24) | (3.12) | (4.26) | (8.76) | |
Cash per Share |
0.09 | 1.49 | 3.69 | 9.64 | |
Shareholders Equity per Share |
(2.92) | (25.01) | (34.20) | (64.30) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.92) | (25.01) | (34.20) | (64.30) | |
Free Cash Flow |
(8.75) | (11.13) | (12.49) | (13.81) | |
Working Capital |
(114.56) | (36.79) | (37.03) | (43.90) | |
Capital Expenditures |
(0.02) | (0.18) | 0.01 | (0.07) | |
Net Current Asset Value |
(115.08) | (98.38) | (109.10) | (113.56) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.59 | 0.57 | (0.01) | 0.00 | |
Net Profit Margin |
(57,506.25%) | 2,033.02% | (772.88%) | 0.00% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.84 | 0.82 | 0.83 | 0.83 | |
Average Payables |
5.41 | 6.28 | 4.18 | 3.22 | |
Average Assets |
24.60 | 33.97 | 38.12 | 42.37 | |
Average Common Equity |
(112.71) | (105.10) | (102.59) | (101.85) |
Columns are period end dates